CD8A and neoplasm: In the absence of CD8+ T-cells, KCL-HO-1i/gemcitabine failed to control tumor growth (Figure 3B and Figure S3E-F), highlighting the fact that tumor control elicited by this dual therapy combination was immune-dependent.